МС №11 2013 Пульмонология легких

МС №11 2013 Пульмонология
10. Вторичный остеопороз у пациентов с хронической обструктивной патологией
легких
Н.Л. Шапорова, д.м.н., профессор, В.И. Трофимов, д.м.н., профессор, ГБОУ ВПО
«ПСПбГМУ им. И.П. Павлова» Минздрава России
Литература
1. Adachi JD, Olszynski WP, Hanley DA, Hodsman AB et al.. Management of corticosteroid–
induced osteoporosis. Semin Arthritis Rheum. 2000 Feb;29(4):228–51.
2. American College of Rheumatology Taskforce on Osteoporosis Guidelines. Recommendations
for the prevention and treatment of glucocorticoid–induced osteoporosis. Arthritis Rheum
1996;39:1791–801.
3. Baranova I. A., Toroptsova N. V., et al. Bone mineral density and fracture frequency in patients
with bronchial asthma. 2nd Int. Congress “Glucocorticoid Ind. Osteoporos”, Italy, 2001: 28.
4. Black D., Cummings S., Karpf D. et al. Randomised trial of effect of alendronate on risk of
fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.
Lancet, 1996, 348, 1535–1541.
5. Black D.M., Boonen S., Cauley J., et al. Effect of once–yearly infusion of Zoledronic acid 5 mg
on spine and hip fracture reduction in postmenopausal women with osteoporosis : the HORIZON
pivotal fracture trial. Abstr. Twenty–eighth annual meeting of ASBMR 2006,V.21, S1,2301.
6. Black D.M., Thompson D.E., Bauer D.C. et al. Fracture risk reduced with alendronate in women
with osteoporosis. The fracture intervention trial. J. Clin. Endocrinol. Metab., 2000,V85,4118–
4124.
7. Chesnut III C., Silverman S., Andriano K., and PROOF Study Group. A randomised trial of
nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the
Prevent Recurrence of Osteoporotic Fractures Study. Am J Med, 2000;109:267–276.
8. Chesnut III C., Skag A., Christiansen C., et al. Effect of oral Ibandronate administered daily or
intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res.
2004;19:1241–1249.
9. Compson JE, Papapoulos SE, Blanchrd F. Report on osteoporosis in the European Community:
Current status and recommendation for the future. Osteoporosis Int 1998; 8: 531–4.
10. Cooper C, Campion G, Melton LJ III. Hip fractures in the elderly: a world–wide projection.
Osteoporosis Int. 1992, 2:285–289.
11. Cranney A, Welch V, Adachi JD, Homik J, Shea B, Suarez–Almazor M, Tugwell P, Wells G.
Calcitonin for preventing and treating corticosteroid–induced osteoporosis. (Cochrane Review),
In; The Cochrane Library, Issue I, 2004.
12. de Nijs R.N., Jacobs J.W., Algra A. et al. Prevention and treatment of glucocorticoid–induced
osteoporosis with active vitamin D3 analogues: a review with meta–analysis of randomized
controlled trials including organ transplantation studies. Osteoporos Int. 2004 Aug;15(8):589–
602.
13. Devogelaer J.P., Goemaere S., Boonen S. et al. Evidence–based guidelines for the prevention
and treatment of glucocorticoid–induced osteoporosis: a consensus document of the Belgian
Bone Club. Osteoporos Int. 2006 Jan;17(1):8–19.
14. Eastell R, Reid DM, Compston JE, Cooper C, et al. A UK consensus group on management of
glucocorticoidinduced osteoporosis: an update. J Intern Med 1998;244:271–92.
15. Ettinger B., Black D., Mitlak B. et al. Reduction of vertebral fracture risk in postmenopausal
women with osteoporosis treated with raloxifene: result from a 3–year randomized clinical trial.
JAMA, 1999, 282, 637–645.
16. Genant HK, Cooper C, Poor G et al. Interim report and recommendation of the World Health
Organization task–force for osteoporosis. Osteoporosis Int. 1999; 10: 259–65.
17. Gennari C, Imbimbo B. Effects of prednisone and deflazacort on vertebral bone mass. Calcif
Tissue Int 1985;37:592–3.
18. Harris S., Watts N., Genant H. et al. Effects of risedronate treatment on vertebral and
nonvertebral fracture in women with postmenopausal osteoporosis: a randomized controlled trial.
Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA, 1999, 282, 1344–
1352.
19. Homik J., Suarez–Almazor ME., Shea B. et.al. Calcium and vitamin D for corticosteroid–
induced osteoporosis. Osteoporos.Int. 1999; 9:75–81.
20. Luengo M, Picado C, Delrio L, Guanabens N et al. Vertebral fractures in steroid dependent
asthma and involutional osneoporosis – a comparative stady. Thorax 1991; 46:803–6
21. Lukert B.P.,Raisz I.G. Glucocorticoid–induced osteoporosis: pathogenesis and management.Ann
Int Med 1990; 112: 352–364
22. Lukert BP, Johnson BE, Robinson RG. Estrogen and progesterone replacement therapy reduces
glucocorticoid–induced bone loss. J Bone Miner Res 1992;7:1063–9.
23. Laan RFJM, Buijs WCAM, van Erning LJTO, Lemmens JAM et al. Differential effects of
glucocorticoids on cortical appendicular and cortical vertebral bone mineral content. Calcif
Tissue Int 1993;52:5–9.
24. Laan RFJM, van Riel PLCM, van de Putte LBA, van Erning LJTO et al. Low–dose prednisone
induces rapid reversible axial bone loss in patients with rheumatoid–arthritis– a randomized,
controlled study. Ann Intern Med 1993;119:963–8.
25. Marshall D., Johnell O., Wedel H. Meta-analysis of how well measures of bone mineral density
predict occurrence of osteoporotic fractures. BMJ 1996; 312:1254-1259
26. McClung M., Omizo M., Minkoff J., et al. Single infusion of Zoledronic acid 5 mg provides
sustained benefits in BMD and biomarkers at 12 months in posmenopausal women with low
bone mineral density and prior Alendronate therapy. Abstr. Twenty–eighth annual meeting of
ASBMR 2006,V21,S1,2313.
27. Melton LJ III Perspectives: how many women have osteoporosis now? J.Bone Miner. Res.,
1995, 10: 175–177.
28. Melton LJ III, Thamer M., Ray N. F., et al. Fractures attributable to osteoporosis: Report from
the national osteoporosis foundation. J. Bone Miner. Res., 1997, 12: 16–22.
29. Melton LJ III. Эпидемиология переломов // В книге Риггз Б.Л., Мелтон Л. Дж. III.
Остеопороз. Этиология, диагностика, лечение. М–СПб: «Бином», «Невский диалект» –
2000. – С. 249–272.
30. Meunier R.J., Roux C., Seeman E., et al. The effects of strontium ranelate on the risk of vertebral
fracture in women with postmenopausal osteoporosis. N. Engl. J. Med. 2004; 350: 459–468.
31. National Osteoporosis Foundation. Osteoporosis: review of evidence for prevention, diagnosis
and treatment and cross–effectiveness analysis. Osteoporosis Int. 1998, 8(Suppl.4): S51–S88.
32. Neer R.M., Arnaud C.D., Zanchetta J.R., et al. Effect of parathyroid hormone (1–34) on fractures
and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J.
Med.,2001,V344,19,1434–1441.
33. Omizo M., McClung M., Minkoff J., et al. A single annual infusion is preferred to oral weekly
treatment in postmenopausal women with low bone mineral density previously treated with
Alendronate. Abstr. Twenty–eighth annual meeting of ASBMR 2006,V21,S1,2313.
34. Peck W.A. The effects of glucocorticoids on bone cells metabolism and function. Adv Exp Med
Biol 1984;171:111–119
35. Ray N., Chan J., Thamer M., Melton LJ III. Medical expenditures for the treatment of
osteoporosis fractures in the United States in 1995: Report from the National Osteoporosis
Foundation. Osteoporosis J. Bone Miner. Res., 1997, 12: 24–34.
36. Recker R.R., Boonen S., Garsia P., et al. The effect of annual treatment with Zoledronic Acid 5
mg bone remodeling: bone histomorphometry results from the HORIZON–PFT. Abstr. Twenty–
eighth annual meeting of ASBMR 2006,V21,S1,2301.
37. Reginster J.Y., Seeman E., De Vernejoul M.C., et al. Strontium ranelate reduce the risk of
nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral
Osteoporosis (TROPOS) Study. J. Clin. Endocrinol. Metab. 2005; 90: 2816–2822.
38. Reginster J–Y., Meunier P.L., Roux C. Strontium ranelate: an antiosteoporotic treatment
demonstrated vertebral and nonvertebral antifracture efficacy over 5 years in postmenopausal
osteoporotic women. Osteoporos. Int. 2006, 17 (Suppl. 1), S11, OC 31.
39. Reid I.R., Ames R.W., Evans M.C., et al. Calcium supplementation reduces bone loss in
postmenopausal women: 2–year placebo–controlled study // New Engl. J. Med., 1993; 328: 460–
464.
40. Resker R.R., Kimmel D.B., Hinders S., Davies K.M. Antifracture efficacy of calcium in elderly
women.// J. Bone Miner. Res., 1994, 9(Suppl.1): 9S
41. Richy F., Ethgen O., Bruyere O., Reginster J.Y. Efficacy of alphacalcidol and calcitriol in
primary and corticosteroid–induced osteoporosis: a meta–analysis of their effects on bone
mineral density and fracture rate. Osteoporos Int. 2004 Apr;15(4):301–10.
42. Riggs B. The mechanisms of estrogen regulation of bone resorption // J. Clin. Invest., 2000; 106:
1203–1204.
43. Riggs B. The pathogenesis of involutional osteoporosis. Seventh Bath Conference on
Osteoporosis,
UK
//
Osteoporosis
Int.
2000,
11(Suppl.1):sl.
Johnston C.C., Slemenda C.W. Pathogenesis of postmenopausal osteoporotic fractures // In:
Osteoporosis. J.C. Stevenson, R. Lindsay (eds). Chapman and Hall Ltd, 1998; p. 53–64.
44. Rizzato G, Tosi G, Schiraldi G, Montemurro L, Sisti DS. Bone protection with salmon calcitonin
(sCT) in the long–term steroid therapy of chronic sarcoidosis. Sarcoidosis 1988;5:99–103.
45. Schurch M–A., Rizzoli R., Mermillod B., et al. A prospective study on socioeconomic aspects of
fracture of the proximal femur. J. Bone Miner. Res., 1996, 11: 1935–1942.
46. Slemenda C.W., Chistian J.C., Williams C.J., et al. Genetic determinants of bone mass in adult
women: a reevalution of the twin model and potential importance of gene interaction in
heritability estimates // J. Bone Miner. Res., 1991, 6: 1227–1933.
47. Toroptsova N., Kovalev V., Ushakova M., Benevolenskaya L. Osteoporosis and osteopenia
prevalence in women population of the Moscow region. Osteoporosis Int. 1998, 8(Suppl.3):19.
48. van Staa T, Leufkens HGM, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and
risk of fractures. J Bone Miner Res 2000;15:993–1000.
49. van Staa T, Leufkens HGM, Cooper C. The epidemiology of corticosteroid–induced
osteoporosis. Osteopros Int 2002;13:777–87.
50. van Staa TP, Bishop N, Leufkens HG, Cooper С Are inhaled corticosteroids associated with an
increased risk of fracture in children? Оsteoporos Int. 2004: 21 [Epub ahead of print]
51. van Staa TP, Leufkens HGM, Abenhaim L, Begaud B et al. Use of oral corticosteroids in the
United Kingdom. Q J Med 2000;93:105–11
52. van Staa, T P, Laan, R F, Barton, IP, Cohen, S., Reid, D M.,Cooper, С. Bone density threshold
and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy.
Arthritis Rheum 2003 Nov;48(11):3224–9
53. World Health Organization. Assesment of fracture risk and its application to screening for
postmenopausal osteoporosis. Who technical report series 843. Geneva:WHO, 1994
54. Белова К.Ю., Ершова О.Б., Коршунов Н.И. Глюкокортикоидный остеопороз: диагностика
и лечение // РМ Ж, 2007 г. № 6, С. 546.
55. Беневоленская Л.И. (ред.). Руководство по остеопорозу. М.: «Бином»; 2003. 91, 430–441.
56. Беневоленская Л.И., Лесняк О.М. (ред.). Клинические рекомендации. Остеопороз:
диагностика, профилактика и лечение. М: «Гэотар–Медиа». 2005, 146–163.
57. Беневоленская Л.И., Никитинская О.А., Торопцова Н.В. Остеопороз – социальная
проблема XXI века // РМЖ,2007 г. № 4, С. 315.
58. Беневоленская Л.И., Торопцова Н.В. Остеопороз в практике семейного врача // РМЖ, 2004
г. № 12, С. 715.
59. Григорьева А.Л., Зоткин Е.Г., Косульникова Е.Н., Николенко Э.С. Возможности
комбинированного препарата кальция и витамина Д (Натекаль Д3) в профилактике
сенильного остеопороза // РМЖ, 2006 г. № 25, С. 1859.
60. Долгих С.В., Мазуров В.И., Матвеева Л.П., Столов С.В Роль и место Миакальцика в
лечении остеопороза // РМЖ, 2007 г. № 22, С. 1669.
61. Дыдыкина И.С. Денситометрическая оценка минеральной плотности костей у больных
ревматоидным артритом. Клиническая ревматология, 1995; 5: 22–39.
62. Ершова О.Б., Семенова О.В., Дегтярев А.А. Результаты проспективного изучения исходов
переломов проксимального отдела бедра у лиц пожилого возраста.//Остеопороз и
остеопатии, 2000; №
63. Зоткин Е.Г., Мазуров В.И. Роль кальция и витамина Д в глобальной профилактике
остеопороза и остеопоротических переломов // РМЖ, 2004 г. № 7, С. 476.
64. Королевская Л.И., Маличенко С.Б. Первичный остеопороз // РМЖ, 2004 г. № 7, С. 483.
65. Лесняк О.М. Социальные и экономические последствия предотвращенного остеопороза и
возможные пути организации его профилактики. Тезисы лекций и доклады. III
Российский симпозиум по остеопорозу. С.–Петербург, 2000:76–77.
66. Лила А.М., Мазуров В.И. Роль Кальцемина адванс в профилактике постменопаузального
остеопороза (результаты 12–месячного клинического исследования) РМЖ, 2007 г, том 15,
№ 26, С. 1991.
67. Лоренс Риггз Б., Л. Джозеф Мелтон III. Остеопороз. СПб.: ЗАО «Издательство БИНОМ»;
2000, 205–207.
68. Михайлов Е.Е., Беневоленская Л.И. «Эпидемиология остеопороза и переломов». В кн.
«Руководство по остеопорозу», Москва, Бином, 2003, стр. 10–53.
69. Михайлов Е.Е., Беневоленская Л.И. «Эпидемиология остеопороза и переломов» в кн.
«Руководство по остеопорозу», Москва, Бином, 2003, стр. 10-53
70. Михайлов Е.Е., Беневоленская Л.И., Аникин С.Г. и др. Частота остеопоротических
переломов основных локализаций среди городского населения России // Научно–
практическая ревматология. – 2001. – №3. – С. 75.
71. Насонов Е.Л., Скрипникова И.А., Насонова В.А. Проблема остеопороза в ревматологии.
М.: «СТИН»; 1997, 375–411.
72. Риггз Б.Л., Мелтон III Л.Дж. Остеопороз. Пер. с англ. М.- СПб.: ЗАО «Издательство
БИНОМ», «Невский диалект», 2000 г. – 560 с.
73. Рожинская Л.Я. Остеопатии эндокринологического генеза. B книге Системный
остеопороз. Москва , 2001: 46–64.
74. Руководство по остеопорозу. Под ред. Л.И.Беневоленской.- М.: БИНОМ. Лаборатория
знаний, 2003. – 524 с.
75. Спиртус Т.В., Михайлов Е.Е., Беневоленская Л.И., МПКТ поясничного отдела
позвоночника и шейки бедра у пациентов из эпидемиологической выборки г. Москва.
Клиническая ревматология. – 1997. – №3. – С. 31–36.
76. Шварц Г.Я. Фармакотерапия остеопороза. – М.: Медицинское информационное агнство,
2002.- 368с.
77. Шостак Н.А. Остеопороз: современные подходы к диагностике и лечению // РМЖ, 2007 г,
том 15, № 26, С. 2003.